Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets
Rhea-AI Summary
Halozyme (NASDAQ: HALO) announced a global collaboration and license agreement with GSK to apply Halozyme's ENHANZE® technology to develop subcutaneous formulations for multiple oncology targets, including antibody drug conjugates (ADCs).
GSK will pay an upfront fee, may pay future milestones, and Halozyme will receive royalties on net sales. The first clinical trial is projected to start in 2026, and the deal includes an option for additional targets.
Positive
- First ENHANZE agreement to include ADCs
- First clinical trial projected to initiate in 2026
- Upfront payment plus potential future milestones
- Royalties on net sales, supporting royalty revenue
Negative
- No quantified financial terms disclosed for upfront or milestone payments
- Clinical and regulatory success for subcutaneous ADCs is not guaranteed
News Market Reaction – HALO
In the May 7 session, HALO declined 1.75%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | Collaboration deal | Positive | +0.7% | Global collaboration and license with Oruka for Hypercon technology. |
| Apr 30 | Earnings scheduling | Neutral | +0.5% | Announcement of date and webcast details for Q1 2026 results. |
| Apr 30 | CFO appointment | Positive | +0.9% | Appointment of Darren Snellgrove as CFO with significant experience. |
| Apr 07 | Collaboration deal | Positive | +0.8% | Global collaboration and license with Vertex for Hypercon technology. |
| Mar 12 | CFO transition | Negative | -4.4% | Interim CFO appointment during ongoing search for permanent finance head. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent partnership and corporate news has generally coincided with modestly positive next-day price reactions, while a governance-related CFO transition saw a more pronounced downside move.
This announcement follows a series of strategic and governance developments for Halozyme. In April–May 2026, Halozyme signed global collaboration and license deals with Oruka and Vertex around its Hypercon™ technology, each including upfront payments, milestones and royalties, and both saw modest positive price reactions. The company also announced upcoming Q1 2026 results and executed CFO transitions, with the interim CFO news on Mar 12, 2026 coinciding with a -4.39% move. Today’s GSK ENHANZE deal extends this collaboration trend into oncology and ADCs.
Key Terms
antibody drug conjugates medical
subcutaneous medical
royalties financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Marks first ENHANZE® agreement to include ADC targets
Collaboration also includes option for additional future targets
First clinical trial projected to initiate in 2026
"We are excited to work with GSK to advance development of several oncology therapeutics. This agreement also marks our first collaboration on subcutaneous delivery of ADCs, where we believe subcutaneous delivery with ENHANZE may meaningfully improve the benefit–risk profile," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "This collaboration reflects the continued recognition of ENHANZE as the gold standard for rapid, large-volume subcutaneous delivery, and underscores the value it provides to a growing number of leading pharmaceutical and biotechnology companies. Extending use of ENHANZE with ADCs represents a meaningful expansion of our potential addressable market, positions us at the forefront of a rapidly growing therapeutic class and reinforces the durability of our high-margin royalty revenue business."
"Novel approaches are required to reduce treatment burden for patients with cancer and help access easier forms of treatment," said Eric Richards, SVP Head of Medicine Development Leaders Oncology, GSK. "We see significant potential for subcutaneous formulations of several promising cancer targets, including ADCs, with ENHANZE and look forward to progressing the first clinical program."
GSK will make an upfront payment to Halozyme and potential future milestone payments. Halozyme will also be entitled to royalties on net sales of products that incorporate ENHANZE®.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V. and Skye Bioscience.
Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at‑home and healthcare‑provider settings. The addition of Surf Bio's polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE® by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx, Vertex Pharmaceuticals and Oruka Therapeutics.
Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in
For more information, visit www.halozyme.com and connect with us on LinkedIn.
Forward Looking Statements
In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning royalty revenue growth, margins and durability, potential new partnerships and innovations, the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery and administration of larger volumes of injectable medications through subcutaneous delivery and potentially lowering the treatment burden, easing treatment access and improving the treatment experience for patients. These forward-looking statements also include statements regarding the product development and commercialization efforts of GSK (including the potential advancement and timing of the initiation of the clinical program, regulatory approval and launch as a result of such efforts and the potential future market opportunity for such products) and Halozyme's potential receipt of payments associated with achievement of certain milestones, and royalties on sales of commercialized products. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue" and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including risks and uncertainties concerning whether development, regulatory and sales-based milestones will be achieved, uncertainties concerning whether collaborative products are ultimately developed, approved or commercialized and the potential future market for such products, unexpected levels of revenue growth, expenditures and costs, unexpected results or delays in development and regulatory review, unexpected regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com
Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-announces-global-collaboration-and-license-agreement-with-gsk-to-develop-subcutaneous-formulations-of-multiple-promising-oncology-targets-302765632.html
SOURCE Halozyme Therapeutics, Inc.